Evidence map›Paper›PMID 37031010›Full record

ReviewParkinsonism & related disorders2023

Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?

Ece Bayram, Lucia Batzu, Bension Tilley, Rhea Gandhi, Priya Jagota, Roberta Biundo, Michela Garon, Tittaya Prasertpan, Claudia Lazcano-Ocampo, K Ray Chaudhuri and 2 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Parkinsonism & related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Ece BayramParkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, CA, USA. Electronic address: drecebayram@gmail.com.
Lucia BatzuDepartment of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK. Electronic address: lucia.batzu@kcl.ac.uk.
Bension TilleyDementia Research Centre, University College London, London, UK; Department of Brain Sciences, Imperial College London, London, UK.
Rhea GandhiParkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Priya JagotaChulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Roberta BiundoDepartment of General Psychology, University of Padua, Padua, Italy; Study Center for Neurodegeneration (CESNE), University of Padua, Padua, Italy.
Michela GaronParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
Tittaya PrasertpanChulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Claudia Lazcano-OcampoDepartment of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Department of Neurology, Hospital Sotero del Rio, Santiago, Chile.
K Ray ChaudhuriDepartment of Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.
Rimona S WeilDementia Research Centre, University College London, London, UK; Movement Disorders Centre, University College London, London, UK.
International Parkinson and Movement Disorder Society Non-Motor Parkinson's Disease Study Group
King's College London · GBThai Red Cross Society · THUK Dementia Research Institute · GBUniversity of California San Diego · USUniversity of Padua · IT

Funding

Web-based Automated Imaging Differentiation of ParkinsonismU01NS119562 · NINDS · UNIVERSITY OF FLORIDA · PI BARMPOUTIS, ANGELOS, OKUN, MICHAEL S · 2021 to 2025
$4.8M
Genetic and Neuropathologic Underpinnings of Sex Differences in Lewy Body DementiasR00AG073453 · NIA · UNIVERSITY OF COLORADO DENVER · PI ECE BAYRAM · 2024 to 2026
$725k
Genetic and Neuropathologic Underpinnings of Sex Differences in Lewy Body DementiasK99AG073453 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAYRAM, ECE · 2022 to 2023
$251k
NIA NIH HHS K99 AG073453NIA NIH HHS R00 AG073453NINDS NIH HHS U01 NS119562Wellcome Trust 205167/Z/16/Z
6 · The paper itself

Abstract

backgroundCognitive impairment is common in Parkinson's disease (PD) and has a substantial impact on quality of life. Despite numerous trials targeting various PD features, we still lack effective treatments for cognition beyond cholinesterase inhibitors.

objectiveTo identify the gaps in recent clinical trials with cognitive outcomes in PD and consider areas for improvement.

methodsWe examined recent clinical trials with cognitive outcomes in PD registered on ClinicalTrials.gov, excluding trials without cognitive outcomes, non-interventional studies, and in atypical Parkinsonian disorders. Included trials were categorized by treatment approach (investigational medicinal product, behavioral, physical activity, device-based). Details of trial design and outcomes were collected.

results178 trials at different stages of trial completion were considered. 46 trials were completed, 25 had available results. Mean follow-up duration was 29.9 weeks. Most common cognitive measure was Montreal Cognitive Assessment. Most were performed in North America or Europe. Majority of the participants identified as non-Hispanic and White. Only eight trials showed improvement in cognition, none showed improvement beyond four months. These included trials of international medicinal products, cognitive and physical interventions and devices. GRADE certainty levels ranged from Moderate to Very Low. Only mevidalen had a Moderate certainty for potential clinical effectiveness.

conclusionsAmongst a large number of trials for cognition in PD, only a small proportion were completed. Few showed significant improvement, with no proven long-lasting effects. Trial design, lack of enrichment for at-risk groups, short follow-up duration, insensitive outcome measures likely contribute to lack of detectable benefit and should be considered in future trials.

Indexed as

Cognitive DysfunctionParkinson DiseaseCholinesterase InhibitorsCognitionHumansQuality of LifeCholinesterase InhibitorsClinical trialsCognitive impairmentParkinson's disease

Identifiers

PMID37031010
PMCPMC10330317
OpenAlexW4361297746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.